Article

Cost of treating heart failure in an Irish teaching hospital.

National Centre for Pharmacoeconomics, St James's Hospital, James's Street, Dublin 8.
Irish Journal of Medical Science (Impact Factor: 0.51). 01/2000; 169(4):241-4. DOI: 10.1007/BF03173523
Source: PubMed

ABSTRACT The prevalence of heart failure is 3 to 20 per 1,000 population, but may exceed 100 per 1,000 in the over 65 age group. Some 1-2% of the total healthcare budget is consumed in the management of heart failure.
As hospital costs account for approximately 70% of this expenditure we determined the cost of treating heart failure in an Irish teaching hospital.
Cost evaluation was from the hospital perspective using a microcosting detailed collection of resources used.
The average cost of a hospital admission for cardiac failure was IR 2,146 Pounds. The average cost per day was IR 193 Pounds. Approximately 75% of hospital costs were associated with ward costs. Medications accounted for 3.5% of total costs.
The availability of Irish cost data is essential for the assessment of the cost-effectiveness of therapeutic interventions for the treatment of heart failure in our healthcare system.

0 Bookmarks
 · 
42 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biventricular pacemakers have been shown to reduce mortality and hospitalizations in heart failure (HF) patients and are indicated for those with a New York Heart Association functional class of III or IV and a QRS interval of >130 ms. However, these devices currently cost in the region of dollar US 33,500 and require replacement upon battery depletion. Therefore, determination of the cost effectiveness of resynchronization therapy is important, although little data have been published to date on this topic. A cost-utility analysis from the healthcare perspective was performed using HF patients who received a biventricular pacing device in the Cleveland Clinic Foundation. The comparator was a similarly profiled group of patients who did not receive the device but were treated medically. A Markov model was used to investigate the cost effectiveness at 1 and 5 years. Second-order Monte-Carlo simulation was used to determine the variability in results, using probabilistic sensitivity analysis. Medical treatment was dominated by biventricular pacemaker treatment at both 1 and 5 years of follow-up. Biventricular device insertion is an economically attractive treatment option for clinically indicated HF patients.
    American Journal of Cardiovascular Drugs 01/2006; 6(2):129-37. · 2.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study examined whether there is a relationship between coded diseases at the time of hospital discharge and costs of hospital re-admission. We carried out a systematic review of data relating to emergency medical patients admitted to St. James' Hospital in Dublin between 1 January 2002 and 31 October 2004. Data on discharges from hospital were analyzed as recorded in the hospital in-patient enquiry (HIPE) system. Of 15,876 episodes recorded among 11,201 patients admitted the number of re-admissions numbered up to 43. Age, year of admission, and frequency of admission were factors associated with increased hospital costs. HIPE coding at first discharge predicted increased costs: codes related to heart failure, pneumonia, stroke, diabetes, malignancy, psychiatric, and anaemia-related codes. Clinical coding using the HIPE database thus strongly predicted hospital costs.
    The European Journal of Health Economics 07/2006; 7(2):123-8. · 2.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heterogeneity of disease severity and clinical trajectory has been described among patients hospitalized with heart failure (HF). However, little is known about the variability in and contributors to costs associated with HF hospitalizations. We examined the distribution of costs associated with a HF diagnosis in a large contemporary hospital database. Diagnosis and procedure codes were systematically used to identify primary inpatient HF admissions to hospitals participating in the PREMIER database 2004-2005. Average costs per day and division of costs among hospital departments were evaluated based on patient and hospitalization characteristics. Total number of hospitalizations was 278,214; 36% had a length of stay (LOS) >5 days. There was a clear association between type of intravenous therapy, LOS, inhospital mortality, and cost. For example, patients initiated on a single intravenous inotrope had a longer mean LOS (9.6 days), greater inhospital mortality rate (14.7%), and higher mean total cost ($18,411) than any other medical therapy administered during hospitalization. The single largest contributor to cost was room and board. Forty-six percent of hospitalizations with diagnosis-related group code 127 (n = 234,204) exceeded average Medicare reimbursement. Variables on admission associated with highest cost hospitalizations were age <75 years, non-black race, male sex, and urban teaching hospital status. Length of stay is the determinant of cost for HF hospitalizations. Use of vasoactive therapy is a marker for longer LOS, higher mortality, and greater costs. Improved reimbursement rates or improved therapeutic options that lessen LOS are required if the costs of HF care are to be minimized.
    American heart journal 06/2008; 155(6):978-985.e1. · 4.65 Impact Factor

Full-text (2 Sources)

View
8 Downloads
Available from
May 15, 2014